Preferred Label : Castleman Disease;

MeSH definition : Large benign, hyperplastic lymph nodes. The more common hyaline vascular subtype is characterized by small hyaline vascular follicles and interfollicular capillary proliferations. Plasma cells are often present and represent another subtype with the plasma cells containing IgM and IMMUNOGLOBULIN A.;

MeSH synonym : castleman's disease; angiofollicular lymphoid hyperplasias; hyperplasia, angiofollicular lymphoid; castleman's tumor; castleman tumor; castlemans tumor; tumor, castleman's; hyperplasia, giant lymph node; lymph node hyperplasia, giant; angiofollicular lymphoid hyperplasia; lymphoid hyperplasia, angiofollicular; castlemans disease; angiofollicular lymph hyperplasia; angiofollicular lymph hyperplasias; hyperplasia, angiofollicular lymph; angiofollicular lymph node hyperplasia; Lymph Hyperplasia, Angiofollicular; Disease, Castlemans; Giant Lymph Node Hyperplasia;

CISMeF synonym : hyperplasias, angiofollicular lymph; glnh; hyperplasias, angiofollicular lymphoid; lymphoid hyperplasias, angiofollicular;

MeSH annotation : DF: note short X ref;

Wikipedia link : https://en.wikipedia.org/wiki/Castleman disease;

Details


Main resources

You can consult :

Large benign, hyperplastic lymph nodes. The more common hyaline vascular subtype is characterized by small hyaline vascular follicles and interfollicular capillary proliferations. Plasma cells are often present and represent another subtype with the plasma cells containing IgM and IMMUNOGLOBULIN A.

https://www.has-sante.fr/jcms/p_3121172/fr/maladie-de-castleman
2019
false
false
false
France
herpesvirus 8, human
chronic disease
critical pathways
herpesviridae infections
hiv infections
adult
child
Castleman Disease
Castleman Disease
continuity of patient care
signs and symptoms
Castleman Disease
Rituximab
practice guideline
Castleman Disease

---
Summary Basis of Decision (SBD) for Sylvant
Siltuximab, 100 mg/vial and 400 mg/vial, Lyophilized powder for solution, intravenous
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?linkID=SBD00193
2015
false
false
false
Canada
French
English
summary of product characteristics
drug approval
canada
siltuximab
siltuximab
siltuximab
drug evaluation
risk assessment
treatment outcome
Interleukin-6
multi-centric castleman's disease
adult
rare diseases
infusions, intravenous
Castleman Disease
antibodies, monoclonal
antibodies, monoclonal

---
http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=FR&Expert=93682
2011
France
scientific and technical information
Castleman Disease
child
Castleman Disease

---
http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=FR&Expert=93686
2011
France
scientific and technical information
Castleman Disease
multi-centric castleman's disease
Multi-centric Castleman's Disease

---
http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=FR&Expert=93685
2011
France
scientific and technical information
Castleman Disease
Castleman Disease

---
http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=FR&Expert=160
2006
France
French
Castleman Disease
rare diseases
diagnosis, differential
Castleman Disease
Castleman Disease
Castleman Disease
incidence
scientific and technical information

---
Nous contacter.
18/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.